Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
5.70
-0.62 (-9.81%)
At close: Jun 12, 2026, 4:00 PM EDT
5.90
+0.20 (3.51%)
After-hours: Jun 12, 2026, 7:29 PM EDT
Seres Therapeutics Employees
Seres Therapeutics had 66 employees as of December 31, 2025. The number of employees decreased by 37 or -35.92% compared to the previous year.
Employees
66
Change (1Y)
-37
Growth (1Y)
-35.92%
Revenue / Employee
$17,379
Profits / Employee
-$710,591
Market Cap
55.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 66 | -37 | -35.92% |
| Dec 31, 2024 | 103 | -130 | -55.79% |
| Dec 31, 2023 | 233 | -198 | -45.94% |
| Dec 31, 2022 | 431 | 98 | 29.43% |
| Dec 31, 2021 | 333 | 178 | 114.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 139 |
| Acrivon Therapeutics | 76 |
| eXoZymes | 32 |
| PDS Biotechnology | 21 |
| Filana Therapeutics | 20 |
| iBio, Inc. | 20 |
| ImageneBio | 17 |
| MiNK Therapeutics | 15 |
MCRB News
- 7 days ago - Seres Therapeutics announces two transactions - TheFly
- 7 days ago - Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 - GlobeNewsWire
- 24 days ago - Seres Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 4 weeks ago - Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics Earnings release: Q1 2026 - Filings
- 5 weeks ago - Seres Therapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease - GlobeNewsWire